The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).
 
Tetsuhito Muranaka
No Relationships to Disclose
 
Satoshi Yuki
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Yasuyuki Kawamoto
No Relationships to Disclose
 
Hiroshi Nakatsumi
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Hideyuki Hayashi
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Bayer Yakuhin; Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Taiho Pharmaceutical; Takeda (Inst)
Travel, Accommodations, Expenses - Kirin Pharmaceuticals; Lilly Japan
 
Atsushi Ishiguro
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Takuto Miyagishima
No Relationships to Disclose
 
Ichiro Iwanaga
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Takashi Kato
No Relationships to Disclose
 
Naoya Sakamoto
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo
 
Yoshito Komatsu
Honoraria - Bayer Yakuhin; Pfizer; Takeda